Physician

Barry F Zeffren, MD

According to 2025 Medicare claims, Barry Zeffren, MD (NPI: 1205908639) practices allergy/immunology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from Madison, IL. This provider's primary affiliated billing organization is ALLERGY & ASTHMA CARE LTD (NPI: 1982824736; TIN: 371319106) and primary practice location at 62034-1702. Zeffren is affiliated with the IRCCO (ACO ID: A2619), participating under the MSSP model.

Zeffren's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 116 traditional Medicare patients, billed 3,483 HCPCS/CPT codes, and received $36,214 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,159 prescription claims across 162 beneficiaries totaling $948,214 in drug costs, led by Dupixent Pen (Dupilumab). DME data shows 73 claims. Open Payments data shows 34 records totaling $611. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $177,195 to $948,214. In contrast, DME billing represents a smaller volume and rose steadily, from $678 to $1,134.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	169	3,606	$38,801
2016	192	4,276	$43,861
2017	192	4,675	$45,942
2018	189	3,829	$39,212
2019	193	4,072	$43,945
2020	130	2,485	$29,531
2021	143	3,388	$42,443
2022	141	4,292	$44,589
2023	132	4,382	$43,214
2024	116	3,483	$36,214

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	146	873	$177,195
2016	160	939	$212,380
2017	159	1,009	$335,315
2018	171	1,021	$346,823
2019	178	1,123	$437,506
2020	146	927	$460,211
2021	144	823	$452,654
2022	154	910	$593,978
2023	156	1,134	$908,067
2024	162	1,159	$948,214

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	32	$392
2016	N/R	N/R	N/R
2017	N/R	59	$806
2018	N/R	41	$636
2019	N/R	49	$738
2020	N/R	26	$1,011
2021	N/R	36	$46,401
2022	N/R	39	$51,262
2023	N/R	55	$56,383
2024	N/R	73	$90,441

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	49	49	$159
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	96	156	$60
94010	Test to measure expiratory airflow and volume	17	21	$17
95044	Test for allergy using skin patch	12	1,003	$4
95004	Test for allergy using allergenic extract	34	1,512	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Pen	Dupilumab	43	1,400	$189,323
Xolair	Omalizumab	57	1,596	$167,561
Hyqvia	Igg/Hyaluronidase,recombinant	17	357	$154,138
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	24	672	$100,404
Fasenra	Benralizumab	16	840	$95,748

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1558	Injection, immune globulin (xembify), 100 mg	N	N/R	13	$52,244
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	17	$31,458
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	17	$5,604
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	13	$1,000
K0552	Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, each	N	N/R	13	$134

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$611	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Barry F. Zeffren, MD?

Tedicare shows public-source Medicare data for Barry F. Zeffren, MD (NPI 1205908639), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Barry F. Zeffren, MD have ACO affiliation data?

Barry F. Zeffren, MD is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619).

What billing organization is linked to Barry F. Zeffren, MD?

Barry F. Zeffren, MD is linked to ALLERGY & ASTHMA CARE LTD (billing NPI 1982824736) in the available physician profile data.

Does Barry F. Zeffren, MD have Open Payments data?

Barry F. Zeffren, MD has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.